Education
About Us
Working with TipRanks
Follow Us
Haemonetics (HAE)
NYSE:HAE
HAE Stock Chart & Stats
$84.04
-$0.34(-0.44%)
At close: 4:00 PM EST
$84.04
-$0.34(-0.44%)
Day’s Range― - ―
52-Week Range$47.32 - $87.32
Previous CloseN/A
Volume53.78K
Average Volume (3M)608.25K
Market Cap
$3.89B
Enterprise Value$3.22B
Total Cash (Recent Filing)$296.43M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)24.5
Beta0.52
Next Earnings
Feb 05, 2026EPS Estimate
1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.27
Shares Outstanding46,809,673
10 Day Avg. Volume333,439
30 Day Avg. Volume608,245
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)3.87
Price to Sales (P/S)2.34
P/FCF Ratio22.33
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda8.60
Forecast
1Y Price Target
$88.43Price Target Upside5.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)4.91
Revenue Forecast (FY)$1.32B
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ProgressPerQseal clinical data indicate safe and effective large-bore closure with faster, safer performance versus a competitor, and regulatory approvals plus an FDA submission for arterial use could support wider adoption.
Financial Performance And GuidanceQuarterly results beat expectations, management raised FY/26 guidance, and margin expansion combined with robust plasma growth point to improving profitability momentum.
Product Portfolio ExpansionAcquisition of Vivasure Medical adds a bioabsorbable patch for sealing large-bore catheter sites, broadening Haemonetics' vascular closure product portfolio and supporting new revenue streams.
Bears Say
Key Account Share Losses And Pricing PressureMaterial market share losses in about fifty key electrophysiology hospital accounts driven by aggressive competitor pricing could reduce revenue and weaken pricing power.
Product-line Decline RiskInterventional Technologies are expected to decline through FY27, which could constrain Haemonetics' top-line growth and earnings potential.
Rising Competitive PressureIncreasing competition from Abbott, Cordis and other entrants in large-bore and venous closure markets may pressure Haemonetics' market share and margins.
Haemonetics News
HAE FAQ
What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was $47.31 and its highest was $87.32 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is $3.89B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s upcoming earnings report date is Feb 05, 2026 which is in 26 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on Nov 06, 2025. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.16.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.25.
How many shares outstanding does Haemonetics have?
Haemonetics has 46,809,673 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of $1.27 in its last earnings report, beating expectations of $1.11. Following the earnings report the stock price went up 32.315%.
Which hedge fund is a major shareholder of Haemonetics?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$88.43 (5.22% Upside)
$88.43 (5.22% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 512.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $98.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.60%
12-Months-Change
Fundamentals
Return on Equity
19.47%
Trailing 12-Months
Asset Growth
-3.29%
Trailing 12-Months
Company Description
Haemonetics
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in organic revenue, adjusted EPS, and gross margin expansion. Plasma and Blood Management Technologies showed robust performance, reinforcing strong cash generation and increased free cash flow guidance. However, overall revenue showed a decline due to portfolio transitions, and Interventional Technologies faced challenges. Despite these lowlights, the call maintained a positive outlook on future growth and profitability.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$88.43
▲(5.22% Upside)
Technical Analysis
Ownership Overview
1.38% Insiders
37.73% Mutual Funds
25.83% Other Institutional Investors
8.81% Public Companies and
Individual Investors